grants_govPAR-25-143
Open
Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)
- Response deadline
- Jan 7, 2028 Due in 448 days
- Date posted
- Oct 31, 2024
- Source
- Open notice
Description
The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (de-implement) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged.All applications must be within the scope of the mission of one of the Institutes/Centers listed above.
Classifications
- NAICS93.279
Documents (1)
- DownloadPAR-25-143-Full-Announcement.htmltext/html422 B
Contacts
- grantsinfo@nih.gov301-402-2541
Similar contracts
- Neural Ensembles & Used Substances (NExUS) Collaboratory: Building a Multimodal Inventory of Cell Ensembles Encoding the Effects of Addictive Substances (U01 Clinical Trial Not Allowed)Due Feb 8, 2027
- Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)Due Jun 16, 2028
- BRAIN Initiative: Integrative Team-Research BRAIN Circuits Program - iBCP (RM1 Clinical Trial Not Allowed)Due Jun 23, 2028
- Limited Competition: Growing Great Ideas: Research Education Course in Entrepreneurship and Product Development for Researchers Studying Drug Use, Drug Misuse, and Drug Addiction (UE5 Clinical Trial Not Allowed)Due Oct 1, 2026
- Science Track Award for Research Transition (START) Program (R03, Clinical Trial Optional)Due Mar 16, 2029
- Avant Garde/Avenir Awards for Investigators Conducting High Risk/High Reward Research on HIV and Substance Use (or Substance Use Disorders) (DP1 Clinical Trial Optional)Due Sep 25, 2028